在与帕金森病相关的慢性不可预测性压力 (CUS) 中,蒙尼丁的保护作用与帕金森病有关
Tanvi Dayanand Pingale1, Girdhari Lal Gupta2,3
1Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, 400 056, Maharashtra, India. tanvi.pingale@gmail.com.
概括
甲诺丁 (FMN) 通过改善运动功能和减少炎症,有效治疗与帕金森病 (PD) 相关的慢性不可预测压力 (CUS). 需要进一步的人体研究来证实这些对帕金森病患者的有希望的发现.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,通常由慢性不可预测的压力 (CUS) 加剧.
- 甲诺丁 (FMN) 是一种7-氧yisoflavone,具有抗氧化和抗炎性质.
- 在CUS相关的PD中,FMN的治疗潜力仍然未被探索.
研究的目的:
- 在CUS相关PD的小鼠模型中研究FMN的疗效.
- 在这个模型中,评估FMN对行为,生化和免疫组织化学参数的影响.
主要方法:
- 在小鼠中使用轮和轻度压力剂诱导了CUS相关的PD.
- 通过腹腔内注射,小鼠接受了不同剂量的FMN (5,10,20 mg/kg) 治疗.
- 评估包括行为测试,生物化学分析炎症标记物和神经递质,以及α-synuclein,BDNF和BCL-2的免疫组织化学.
主要成果:
- 在CUS+ROT模型中,FMN治疗显著缓解了核心CUS症状,改善了认知功能,步态和协调.
- 在FMN中,表现出一种剂量依赖的,促炎性细胞因子 (IL-1β,TNF-α,IL-6) 的降低.
- FMN增加了多巴胺,上腺素和血清素水平,降低了α-synuclein表达,并增强了BDNF和BCL-2表达,促进了神经元的生存.
结论:
- 福蒙尼丁显示出重要的治疗潜力,用于管理与帕金森病相关的慢性不可预测的压力.
- FMN有效地改善运动缺陷和神经炎症,可能通过涉及BDNF和BCL-2的神经保护机制.
- 需要进一步的临床研究来验证FMN在人类PD患者中的疗效.
相关概念视频
Parkinson's Disease: Treatment
162
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
162
Parkinson's Disease: Overview
353
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
353
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K


